Effects of chromium and yeast supplements on carbohydrate and lipid metabolism in diabetic men.
Diabetes mellitus has been shown to develop as a consequence of chromium (Cr) deficiency in experimental animals and in humans sustained by prolonged total parenteral nutrition. Prior limited trials in humans had indicated that Cr supplements, in either inorganic or organic form, may improve carbohydrate utilization. We report here a clinical double-blind, random crossover trial of inorganic Cr trichloride, a brewer's yeast that contained Cr as glucose tolerance factor (GTF), a brewer's yeast extract without GTF, and a placebo. Forty-three outpatient diabetic men received three of these supplements for 4 mo each. Subgroups included 21 ketosis-prone men; 7 ketosis-resistant, nonobese men; and 15 ketosis-resistant obese men. Chromium levels were followed pre- and posttreatment in hair, red blood cells, plasma, and urine. Response of carbohydrate metabolism to treatment was assessed in terms of change in insulin requirements, fasting plasma glucose, plasma cholesterol, and triglycerides, as well as change in plasma glucose, glucagon, and insulin or C-peptide levels in response to a standard meal. In some men, these parameters were also measured after i.v. tolbutamide. Both the inorganic and organic oral Cr supplements increased measurable body pools of Cr in hair and red blood cells by about 25%. However, fasting plasma glucose and lipids and the glucose response to either the standard meal or to tolbutamide were not significantly altered by any of the treatments. Despite this lack of effect on carbohydrate levels, the ketosis-resistant subgroups demonstrated a significant increase in postprandial insulin after treatment with the brewer's yeast that contained GTF.
D001786:Blood Glucose / Q000032:analysis; D002096:C-Peptide / Q000097:blood; D050260:Carbohydrate Metabolism; D002857:Chromium / Q000032:analysis / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004311:Double-Blind Method; D004912:Erythrocytes / Q000032:analysis; D005934:Glucagon / Q000097:blood; D006197:Hair / Q000032:analysis; D006801:Humans; D007328:Insulin / Q000097:blood; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D014556:Urine / Q000032:analysis; D015002:Yeast, Dried / Q000494:pharmacology / Q000627:therapeutic use*
D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D008055:Lipids; D002857:Chromium; D005934:Glucagon